← hubDrugs

3 sources

← All substances
🔗 MergedCompareTripSitPharmacologyDailyMed

Collated from TripSit, Pharmacology, DailyMed. Where sources differ (e.g. dosing), Compare shows them side by side.

Sections

Also known as n,n-diallyltryptamine, diallyltryptamineTS

Psychedelic drug of the tryptamine class.TS

Oral

Route dataTripSit

ThresholdLightCommonStrongHeavy
20–40 mg40–60 mg—+
060 mg
LightCommonStrongHeavy
Onset15–45 minutes
Total3–6 hours
After-effects1–4 hours
OnsetCome-upPeakOffset

🧬 Receptor activityPH

TargetActionAffinitySource
5-hydroxytryptamine receptor 2BKi 61.66 nMCHEMBL
Sigma non-opioid intracellular receptor 1Ki 100 nMCHEMBL
5-hydroxytryptamine receptor 1AKi 100 nMCHEMBL
Alpha-2A adrenergic receptorKi 123.03 nMCHEMBL
Histamine H1 receptorKi 125.89 nMCHEMBL
Sodium-dependent serotonin transporterKi 151.36 nMCHEMBL
Alpha-2B adrenergic receptorKi 302 nMCHEMBL
UncheckedKi 354.81 nMCHEMBL
5-hydroxytryptamine receptor 1EKi 380.19 nMCHEMBL
5-hydroxytryptamine receptor 2CKi 389.05 nMCHEMBL
D(3) dopamine receptorKi 676.08 nMCHEMBL
5-hydroxytryptamine receptor 1DKi 691.83 nMCHEMBL
5-hydroxytryptamine receptor 2AKi 707.95 nMCHEMBL
Alpha-2C adrenergic receptorKi 891.25 nMCHEMBL
Sodium-dependent noradrenaline transporterKi 1000 nMCHEMBL
Sodium-dependent dopamine transporterKi 1258.93 nMCHEMBL
Alpha-1B adrenergic receptorKi 1258.93 nMCHEMBL
Alpha-1A adrenergic receptorKi 1659.59 nMCHEMBL
5-hydroxytryptamine receptor 6Ki 1737.8 nMCHEMBL
Kappa-type opioid receptorKi 2454.71 nMCHEMBL
5-hydroxytryptamine receptor 7Ki 10000 nMCHEMBL
5-hydroxytryptamine receptor 5AKi 10000 nMCHEMBL
Alpha-1D adrenergic receptorKi 10000 nMCHEMBL
5-hydroxytryptamine receptor 1BKi 10000 nMCHEMBL
Mu-type opioid receptorKi 10000 nMCHEMBL
Histamine H3 receptorKi 10000 nMCHEMBL
D(2) dopamine receptorKi 10000 nMCHEMBL
‹ PrevPage 1 / 11–27 of 27Next ›

Mechanism of actionDM

Dalteparin is a low molecular weight heparin with antithrombotic properties. It acts by enhancing the inhibition of Factor Xa and thrombin by antithrombin. In humans, dalteparin potentiates preferentially the inhibition of coagulation Factor Xa, while only slightly affecting the activated partial thromboplastin time (APTT).

PharmacodynamicsDM

Doses of FRAGMIN Injection of up to 10,000 anti-Xa units administered subcutaneously as a single dose or two 5,000 units doses 12 hours apart to healthy subjects did not produce a significant change in platelet aggregation, fibrinolysis, or global clotting tests such as prothrombin time (PT), thrombin time (TT) or APTT. Subcutaneous administration of doses of 5,000 units twice daily of FRAGMIN for seven consecutive days to patients undergoing abdominal surgery did not markedly affect APTT, Platelet Factor 4 (PF4), or lipoprotein lipase.

Plan when to take DALT — see where onset, peak and comedown land on the clock

Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.